Trial · NCT02304757
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
NCT02304757, Not applicable, Completed, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; results first posted 2021-10-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis. Trials, record NCT02304757. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02304757
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
- NCT number
- NCT02304757
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 142 participants, actual
- Lead sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Conditions
- Differentiated Thyroid Cancer, Osteoporosis
- Interventions
- 99Tc-MDP, Fosamax
- First posted
- 2014-12-02
- Last updated
- 2021-11-17
- Results first posted
- 2021-10-18
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change of Bone Mineral Density in Lumbar and Hip | baseline, 6 months, and 12 months | Percent change of bone mineral density in lumbar and hip by dual energy x-ray absorptiometry |
| Secondary | Bone Turnover Markers | baseline and 12 months | bone turnover markers including C-telopeptides of type I collagen (CTX), Type I N-procollagen terminal propeptide(PINP) |
| Secondary | Health Related Quality of Life by 36-item Short Form Health Status Survey Questionnaire (0-100) | baseline, 6 months, and 12 months | The health related quality of life was measured by 36-item Short Form Health Status Survey questionnaire (SF-36). The minimum and maximum values were 0 and 100, respectively. Higher scores mean a better a better outcome. The questionnaire includes 36 items that can be classified into the following eight health status subscales: Physical Functioning, Physical Role Limitations, Bodily Pain, General Health Perception, Vitality, Social Functioning, Emotional Role Limitations, and Mental Health. A standardized Physical Component Summary and a standardized mental component score were calculated. The physical component summary and mental component summary represent the deviation from the reference population in Sweden. Higher scores mean a better a better outcome. |
| Secondary | Side Effects | 6 months, and 12 months | A transient rash and phlebitis, gastrointestinal reaction. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change of Bone Mineral Density in Lumbar and Hip | baseline, 6 months, and 12 months | percentage change | MEAN | |
| SECONDARY | Bone Turnover Markers | baseline and 12 months | ng/ml | MEAN | |
| SECONDARY | Health Related Quality of Life by 36-item Short Form Health Status Survey Questionnaire (0-100) | baseline, 6 months, and 12 months | scores on a scale | MEAN | |
| SECONDARY | Side Effects | 6 months, and 12 months | side effects | NUMBER |
Source ClinicalTrials.gov
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change of Bone Mineral Density in Lumbar and Hip | 99Tc-MDP | Percentage change of lumbar spine at month 6 | 3.0 | Standard Deviation 6.6 | percentage change |
| Percent Change of Bone Mineral Density in Lumbar and Hip | Fosamax | Percentage change of lumbar spine at month 6 | 3.2 | Standard Deviation 7.1 | percentage change |
| Percent Change of Bone Mineral Density in Lumbar and Hip | 99Tc-MDP | Percentage change of lumbar spine month 12 | 3.8 | Standard Deviation 10.9 | percentage change |
| Percent Change of Bone Mineral Density in Lumbar and Hip | Fosamax | Percentage change of lumbar spine month 12 | 5.1 | Standard Deviation 6.1 | percentage change |
| Percent Change of Bone Mineral Density in Lumbar and Hip | 99Tc-MDP | Percentage change of total hip at month 6 | 0.9 | Standard Deviation 7.7 | percentage change |
| Percent Change of Bone Mineral Density in Lumbar and Hip | Fosamax | Percentage change of total hip at month 6 | 4.9 | Standard Deviation 7.7 | percentage change |
| Percent Change of Bone Mineral Density in Lumbar and Hip | 99Tc-MDP | Percentage change of total hip at month 12 | 5.1 | Standard Deviation 17 | percentage change |
| Percent Change of Bone Mineral Density in Lumbar and Hip | Fosamax | Percentage change of total hip at month 12 | 4.6 | Standard Deviation 9.6 | percentage change |
| Bone Turnover Markers | 99Tc-MDP | PINP before treatment | 43.7725 | Standard Deviation 14.74802 | ng/ml |
| Bone Turnover Markers | Fosamax | PINP before treatment | 29.255 | Standard Deviation 29.46603 | ng/ml |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 99Tc-MDP | 70 | |
| Overall Study | STARTED | Fosamax | 72 | |
| Overall Study | COMPLETED | 99Tc-MDP | 70 | |
| Overall Study | COMPLETED | Fosamax | 72 | |
| Overall Study | NOT COMPLETED | 99Tc-MDP | 0 | |
| Overall Study | NOT COMPLETED | Fosamax | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | upper gastrointestinal (GI) adverse events | Gastrointestinal disorders | 99Tc-MDP | 0 | 70 | 0 |
| other | upper gastrointestinal (GI) adverse events | Gastrointestinal disorders | Fosamax | 6 | 72 | 72 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 99Tc-MDP | 0 | 70 |
| Total, all-cause mortality | Fosamax | 0 | 72 |
| Total, other adverse events | 99Tc-MDP | 0 | 70 |
| Total, other adverse events | Fosamax | 6 | 72 |
| Total, serious adverse events | 99Tc-MDP | 0 | 70 |
| Total, serious adverse events | Fosamax | 0 | 72 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| 99Tc-MDP vs Fosamax: deaths from any cause | Trial comparisons |
| 99Tc-MDP vs Fosamax: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02304757
GET https://conductscience.org/api/trials/v1/NCT02304757/results?page=2